The average one-year price target for Fosun International Limited - Depositary Receipt (OTCPK:FOSUY) has been revised to $20.06 / share. This is an increase of 59.35% from the prior estimate of $12.59 dated February 23, 2026. These figures represent aggregate analyst targets comp
The average one-year price target for Fosun International Limited - Depositary Receipt (OTCPK:FOSUY) has been revised to $20.06 / share. This is an increase of 59.35% from the prior estimate of $12.59 dated February 23, 2026. These figures represent aggregate analyst targets comp
As missile threats grow faster and more maneuverable, detecting and tracking them presents new challenges. Explore how Lockheed Martin’s Next Gen OPIR GEO is designed to improve infrared sensing and support timely military decision-making.
As missile threats grow faster and more maneuverable, detecting and tracking them presents new challenges. Explore how Lockheed Martin’s Next Gen OPIR GEO is designed to improve infrared sensing and support timely military decision-making.
Retired U.S. Army Lt. Col. Darin Gaub discusses President Donald Trump's options in Iran as negotiations continue and U.S. forces expand efforts to disrupt Iranian weapons shipments.
Onconetix, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on November 4, 2026, to effect a one-for-ten (1:10) reverse stock split of its issued and outstanding common stock. The r
Compass Therapeutics, Inc. reported a net loss of $27.2 million, or $0.15 per common share, for the quarter ended September 30, 2026, compared to a net loss of $14.3 million, or $0.08 per common share, for the same period in 2025. Research and development expenses increased to $2